Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Orion Oyj announced an agreement with Qilu Pharma Europe to commercialize an intravenous pembrolizumab biosimilar in Europe. Orion will gain exclusive rights to distribute, market, and sell Qilu's product.
Orion Pharma has signed an agreement with Qilu Pharma Europe to distribute, market, and sell an intravenous pembrolizumab biosimilar across Europe. Qilu will supply the biosimilar and receive profit share, development, regulatory, and sales milestone payments.